4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Merkel Cell Carcinoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 227 ongoing clinical trials involving Merkel Cell Carcinoma
Of the 227 trials,91 trials are in Phase I
Furthermore, 72 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Merkel Cell Carcinoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Merkel Cell Carcinoma, an Oncology condition. The largest number of ongoing clinical trials for Merkel Cell Carcinoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Merkel Cell Carcinoma-related drug trials.

National Cancer Institute US: The leading ongoing Merkel Cell Carcinoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Merkel Cell Carcinoma-related ongoing clinical trials.

Incyte Corp, Fate Therapeutics Inc, H. Lee Moffitt Cancer Center & Research Institute Inc and Bristol-Myers Squibb Co are among other notable clinical trial sponsors involved in Merkel Cell Carcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Merkel Cell Carcinoma

Pembrolizumab (Keytruda) and Avelumab (MSB-0010718C, Bavencio) are among the key marketed drugs involving Merkel Cell Carcinoma.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Pembrolizumab is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab was first approved in 2014 and is marketed globally in the US, UK, France , Germany, China and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.

Avelumab (MSB-0010718C, Bavencio) is a programmed human IgG1 lambda monoclonal antibody. It functions via Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Inhibitor mechanism of action. Avelumab is formulated as solution and concentrate solution for intravenous route of administration. Avelumab was first approved in 2017 and is marketed globally in the US, UK, France, Germany and Japan by several prominent pharma giants including EMD Serono Inc.